A5079788340- Diabetes Treatment and Management
- Heart Failure Treatment and Management
- Pancreatic function and diabetes
- Atrial Fibrillation Management and Outcomes
- Respiratory and Cough-Related Research
- Asthma and respiratory diseases
- Neuroendocrine Tumor Research Advances
- Cerebrovascular and Carotid Artery Diseases
- Potassium and Related Disorders
- Cardiovascular Function and Risk Factors
- Acute Ischemic Stroke Management
- Allergic Rhinitis and Sensitization
- Adenosine and Purinergic Signaling
- Inhalation and Respiratory Drug Delivery
- Cardiac pacing and defibrillation studies
- Pancreatitis Pathology and Treatment
- Blood Pressure and Hypertension Studies
- Obstructive Sleep Apnea Research
- Clinical practice guidelines implementation
- Hormonal Regulation and Hypertension
- Statistical Methods in Clinical Trials
- Pharmaceutical Practices and Patient Outcomes
- Cardiac Arrhythmias and Treatments
- Analytical Methods in Pharmaceuticals
- Metabolism, Diabetes, and Cancer
Boehringer Ingelheim (Germany)
2012-2024
King's College Hospital NHS Foundation Trust
2023
Universitätsklinikum Würzburg
2022
Boehringer Ingelheim (United Kingdom)
2012-2017
University of Florida
2017
Columbus Oncology and Hematology Associates
2017
University of Calgary
2012
University of Duisburg-Essen
2012
National Institute of Neurological Disorders and Stroke
2012
National Institutes of Health
2012
Dabigatran is an oral direct thrombin inhibitor that has been shown to be effective alternative warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran mechanical heart valves.In this phase 2 dose-validation study, we studied two populations patients: those who had undergone aortic- or mitral-valve replacement within past 7 days and such at least 3 months earlier. Patients were randomly assigned a 2:1 ratio receive either warfarin. The selection initial dose (150,...
Abstract The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic failure, but whether also improves clinical outcomes when initiated who are hospitalized for acute is unknown. In this double-blind trial (EMPULSE; NCT04157751 ), 530 a primary diagnosis de novo decompensated regardless left ventricular ejection fraction were randomly assigned to receive 10 mg once daily placebo. Patients...
Abstract Aims Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects the sodium–glucose cotransporter 2 inhibitor empagliflozin on decongestion-related endpoints in EMPULSE trial (NCT0415775) were evaluated. Methods results A total 530 hospitalized AHF randomized 1:1 to either 10 mg once daily or placebo 90 days. outcomes investigated were: weight loss (WL), WL adjusted mean loop diuretic dose (WL-adjusted), area...
Background: Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, quality life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve status in chronic failure, but their effect on these outcomes is not well characterized. We investigated the effects inhibitor empagliflozin symptoms, life, using Kansas City Cardiomyopathy Questionnaire (KCCQ) EMPULSE trial (Empagliflozin Hospitalized With Acute Heart...
Treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors improves outcomes in patients chronic heart failure (HF) reduced ejection fraction. There is limited experience the in-hospital initiation of SGLT2 acute HF (AHF) or without diabetes. EMPULSE designed to assess clinical benefit and safety inhibitor empagliflozin compared placebo hospitalized AHF. a randomized, double-blind, parallel-group, placebo-controlled multinational trial comparing (10 mg once daily) placebo....
Abstract Aim The sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical outcomes in patients hospitalized for acute heart failure. In with chronic failure, SGLT2 inhibitors cause an early decline estimated glomerular filtration rate (eGFR) followed by a slower eGFR over time than placebo. However, the effects of on renal function during hospital admission failure remain largely unknown. Methods and results Between 1 5 days after hospitalization 530 >20...
High blood pressure is one of the main risk factors for cerebral white matter lesions (WMLs). There limited evidence from randomized trial that pressure-lowering able to slow WML progression. We investigated whether telmisartan prevents progression in imaging substudy Prevention Regimen Effectively Avoiding Second Strokes (PRoFESS) trial.This predefined comprised 771 patients (mean age, 65 years) with recent ischemic stroke noncardioembolic origin who received or placebo during a mean...
Antithrombotic management of patients with atrial fibrillation ( AF ) undergoing coronary stenting is complicated by the need for anticoagulant therapy stroke prevention and dual antiplatelet stent thrombosis events. Triple antithrombotic therapy, typically comprising warfarin, aspirin, clopidogrel, associated a high risk bleeding. A modest‐sized trial oral anticoagulation warfarin clopidogrel without aspirin showed improvements in both bleeding thrombotic events compared triple but large...
The EMPULSE trial evaluated the clinical benefit of empagliflozin versus placebo using stratified win ratio approach in 530 patients with acute heart failure (HF) after initial stabilization. We aim to elucidate how this method works and what it means, thereby giving guidance for use future trials.
Abstract Aim The EMPULSE (EMPagliflozin in patients hospitalised with acUte heart faiLure who have been StabilizEd) trial showed that, compared to placebo, the sodium–glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) improved clinical outcomes of hospitalized for acute failure (HF). We investigated whether efficacy and safety were consistent across spectrum left ventricular ejection fraction (LVEF). Methods results A total 530 de novo or decompensated HF included irrespective LVEF....
Asthma is characterized by a complex interaction of inflammatory mediators. The prostaglandin D2 receptor, chemoattractant receptor-homologous molecule on Th2 cells (CRTH2), plays pivotal role in the pathogenesis allergic airway inflammation.To ealuate efficacy, safety, and pharmacokinetics BI 671800, CRTH2 antagonist, when added to inhaled corticosteroid therapy adult patients with symptomatic asthma.In this phase IIa, 12-week, randomized, double-blind, three-period, four-treatment,...
2623 Background: BI 765063 is a humanized IgG4 monoclonal antibody antagonist of SIRPα (Signal Regulatory Protein α), which blocks the “don't eat me” signal SIRPα/CD47 axis, critical innate immune checkpoint. expressed on myeloid cells. binds to V1 allele with high affinity and V2 low affinity. lacks SIRPγ binding preserve T-cell activation. We report results completed monotherapy dose escalation in patients advanced solid tumors. Methods: This study involves step 1 determine dose-limiting...
Background and Purpose— Silent brain infarctions are associated with an increased risk of stroke in healthy individuals. Risk recurrent patients both symptomatic silent infarction (SBI) has only been investigated cardioembolic the European Atrial Fibrillation Trial. We assessed whether recent noncardioembolic SBI detected on MRI at for stroke, other cardiovascular events, mortality. Methods— The prevalence was 1014 enrolled imaging substudy Prevention Regimen Effectively Avoiding Second...
Abstract BI 1021958, a novel antagonist of the chemoattractant‐receptor‐homologous molecule (CRTH2), targets airway inflammation in asthma by inhibiting prostaglandin binding to CRTH2 receptors. Two phase 1 studies assessed 1021958 safety/tolerability and pharmacokinetics (PK)/pharmacodynamics (PD) following single doses healthy men multiple men/women with well‐controlled asthma. Studies had 2 parts: placebo‐controlled, fixed‐sequence, single‐blind, single‐rising‐dose part (n = 56)...
Abstract Purpose This drug utilization study of ivabradine evaluated prescriber compliance with the new risk minimization measures (RMMs), communicated starting 2014 following preliminary results from SIGNIFY study. Methods was a multinational (five European countries) chart review two periods: pre‐RMM and post‐RMM. Patients initiating for chronic stable angina pectoris in routine clinical practice were identified across general practitioners specialists. The primary outcome analysis RMMs,...
Abstract Introduction Each week, diabetes leads to more than 700 strokes, almost 600 heart attacks and 2000 instances of failure, in addition being the single most common cause chronic kidney disease UK.1 The NHS spends 10% its annual budget on with 80% that treating complications diabetes.2 Pharmacists have a crucial role optimise medication diabetic patients prevent future problems. Aim To assess general practices (GP) compliance national recommendations Quality Outcomes Framework for...